anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine, gastroenterology, pulmonology. SUBSTANCE: invention relates to methods for treatment of erosive injuries in gastroduodenal region resistant to usual therapy in patients with bronchial asthma. Method involves prescription oral systemic glucocorticoids in the dose 10-15 mg per a day (as measured for prednisolone) for 10-14 days for intake. Method provides healing erosions due to elimination of immune disorders in stomach and intestine mucosa. EFFECT: enhanced effectiveness of treatment. 1 ex
All exercise participants will be prescribed exercise that meets guidelines of the American College of Obstetricians and Gynecologists (ACOG), American College of Sports Medicine (ACSM), and the American Heart Association (AHA); 150 minutes per week, moderate intensity (60-80% aerobic capacity, Rating of Perceived Exertion, RPE, 12-15) per week. These limits are the same as those that generated previous positive findings for our preliminary data. The AE group will exercise on aerobic machines (i.e. treadmill, elliptical, bicycle) for all of their sessions.
PURPOSE: A composition containing medicinal herb fermentation or extract thereof for preventing and treating obesity or hyperlipidemia is provided to ensure antiobesity and anti-hyperlipidemia. CONSTITUTION: A health food for preventing and treating obesity or hyperlipidemia contains medicinal herb fermentation containing Lycii Radicis Cortex, Atractylodis Rhizoma, and Mori Fructus or extract of the fermentation as an active ingredient. The health food is a beverage. The extract is isolated using water, low alcohol of 1-4 carbon atoms, or mixture solvent thereof. The fermentation is obtained using Bifidobacterium longum or Bifidobacterium breve. A pharmaceutical composition for preventing and treating obesity or hyperlipidemia contains the medicinal herb fermentation or extract of the fermentation as an active ingredient.
<P>PROBLEM TO BE SOLVED: To provide a skin-protecting composition for improving skin roughness, enhanced in humidity-retaining and skin protecting effects by improving feelings in use such as sticky and slimy feeling.  <P>SOLUTION: The skin-protecting composition contains a fluorine-based polymer and a polyhydric alcohol. The fluorine-based polymer is selected from a group having a perfluoropolyether group or a perfluoropolyether group having a modified terminal group. Particularly, a perfluoropolyether group having a phosphate group-modified terminal group is preferable. The polyhydric alcohol is not limited as far as it is used as a conventional pharmaceutical, a quasi drug and a cosmetic, but one selected from the group consisting of 1,3-butylene glycol, diglycerol, glycerol, dipropylene glycol, propylene glycol, polyethylene glycol, diglycerol trehalos, sorbitol and maltitol is preferable.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Participants randomized to Arm 2 will receive short-course RT and mFOLFOX regimen, except that participants will not receive any of the study drug. After completing the last planned dose of mFOLFOX, participants will be considered off-protocol directed therapy and undergo planned TME, per institutional standards, and proceed to the follow-up portion of this study.
Participants will attend 4 education sessions focusing on interaction of beliefs, behaviors and symptoms on falls. They will be taught self-management principles to modify their fall risk.
Data for this cross-sectional study were collected from a convenient sample of patients aged 6-18 years with headache complaints who presented to a tertiary care pediatric neurology outpatient clinic between April 2022 and April 2023. The sampling size was determined as 88 at the beginning of the study and 127 patients were reached in our study. The inclusion criteria were determined as patients aged 6-18 years with headache complaints who applied to the pediatric neurology outpatient clinic of a training and research hospital, and the absence of any orthopedic, neurological, etc. disease that would prevent physical activity. The exclusion criteria were determined as having communication problems that would not allow evaluation and having a history of additional chronic diseases that would prevent physical activity. All participants filled out a case evaluation form including demographic information, information about headache complaints, and scores of the questionnaire results. Participants completed the Tampa Kinesiophobia Scale (TKS) for kinesiophobia assessment. The TKS consists of 17 questions inquiring about the increase in pain with movement, fear of injury, and avoidance of movement due to pain. The International Fall Efficacy Scale (IFES) used in our study is a questionnaire consisting of 16 questions that provide information about the level of fear of falling during daily life activities. In our study, the visual analog scale (VAS), one of the most commonly used, oldest, and best validated scales, was used to measure pain intensity. The short form of the International Physical Activity Questionnaire (IPAQ)- consisting of seven questions- was used in our study. In the questionnaire, respondents report the duration and frequency of their activities in the previous week. Measuring the quality of life of the individual with psychological tests is important for determining the quality of life of patients before and after treatment, evaluating the effectiveness and side effects of medical interventions, guiding health policies, and conducting medical research. The Quality of Life Scale for Children (QoLSC) is a general quality of life scale that is widely used in research and evaluates the physical and psychosocial experiences of children between the ages of 2 and 18, independent of illness.
The importance of radioresistance in cervical cancer treatment failure indicates that certain biomarkers may be useful for cervical cancer treatment individualization. Several biomarkers of cervical cancer radioresistance have been previously studied and proposed; however, none of these has been the subject to further clinical studies and implemented into clinical practice. Recently, a panel of three protein coding genes (ANXA2-NDRG1-STAT1) differently expressed in radiosensitive LACC patients compared with the radioresistant ones, has been proposed by our institution. The population of LACC patients included in a previous study was treated with neo-adjuvant CTRT followed by radical surgery. However, to date, no study has analyzed the role of the gene expression signature of the three RNA species (ANXA2-NDRG1-STAT1) to predict radiosensitivity/resistance in cervical cancer patients undergoing exclusive CTRT. The previously validated three-gene signature may enable stratification in LACC patients treated with the current standard of care, represented by exclusive CTRT.
The present invention provides a method of altering remodeling of chromatin in a cell comprising administering to the cell a compound that modulates an interaction of a subunit of a chromatin remodeling complex and a domain within a protein. The compound modulates the interaction by inhibiting or enhancing the subunit of the chromatin remodeling complex and the domain within the protein. The protein may be a transcription factor. The domain may be a nucleic acid binding domain or an activation domain. The nucleic acid binding domain, such as peptide or an artificial zinc-finger domain. The first peptide may be linked to a second protein to form a fusion protein. The nucleic acid may be DNA or RNA. The chromatin remodeling complex may be SWI/SNF, RSC, NURF, CHRAC, ACF, NURD and RSF. The remodeling complex may be tissuespecific. In particular the chromatin remodeling complex may be one of the following SWI/SNF subunits: BRG1, BRM, BAF 155, BAF 170, Inil, BAF 60, BAF 47, or BAF 57. The subunit may be associated with at least one other subunit. The SWI/SNF complex may be E-RC1.
ABSTRACT OF THE DISCLOSURE    The invention provides for the production of aqueous extracts of low fat- and other contamenant content which hinder further phases of the production, with extremely high heparin content. The process is effected by subjecting a heparin-enriched, amorphous grannular, retentive raw material of 90-95 weight % dry substance content and of large specific surface to intermittent or continuous counterflow extraction with a salt solution in the temperature range and at the pH value specified optionally for the given processing system and raw material. During the counterflow extraction in contrast with the extracts of 20-40 ml heparin concentra-tion produced so far, heparin-containing aqueous extracts of minimum 120 NE/ml (NE= international unit) activity can be produced, from which the heparin can be isolated by contin-uous processing. Particularly favouable is continuous counter-flow extraction in a U-extractor divided into cells. The advantage of the process is that the programmed variation of the various parameters is not necessary in the extraction, the heparin concentration of the extracts is high, the volum-etric capacity of the equipment is reducible, and the degree of utilization can be improved. Furthermore due to the more selective extraction, implementation of the further phases of the production is more efficient.
Single Arm study In this study, the subject will act as their own control. On Day 1 of the two day study, the subject will be observed while treated on their standard EVD. On Day 2, the subject will be treated with the Smart External Drain (SED).
Cohort A: 3 doses of amoxicillin daily for 7 days (n=14). Follow up 12 months.
PROBLEM TO BE SOLVED: To obtain a gel material for cosmetic capable of easily preparing without damaging physical properties, gentle to human body, having excellent functions besides ultraviolet absorptivity, etc., by including silk gel as a principal component. SOLUTION: This material includes silk gel as a principal component and preferably adjusting pH 3.0-6.0. The above-mentioned silk gel is obtained by refining silk material (e.g. silk waste, damaged concoon, etc.), using sodium carbonate, sodium bicarbonate, etc., dissolving the refined material in an aqueous solution of an inorganic acid salt, preferably 30-60 wt.% of calcium chloride solution, preparing silk solution by removing salt from the solution by carrying out dialysis and gelatinizing the silk solution by using an acid, for example, citric acid, tartaric acid, succinic acid, fumaric acid, glycolic acid, hydrochloric acid and phosphoric acid. The above-mentioned silk gel can be used not only alone but also used as a cosmetic gel by properly cutting and crushing the gel adding moisturizer, medicinal oil, etc., if required.
Down syndrome (DS) is a complex condition associated with multiple medical, developmental, and behavioral concerns. A prospective, longitudinal clinical database was integrated into a specialty Down Syndrome Program, with the goals of better understanding the incidence, course, and impact of co-occurring medical, neurodevelopmental, and mental health conditions in DS. We describe the process of developing the database, including a systematic approach to data collection and database infrastructure, and report on feasibility, challenges, and solutions of initial implementation. Between March 2018 and November 2021, data from 842 patients (ages 4.8 months to 26 years) was collected. Challenges included caregiver form completion as well as time and personnel required for successful implementation. With full integration into clinical visit flow, the database proved to be feasible. The database enables identification of patterns of development and health throughout the lifespan and it facilitates future data sharing and collaborative research to advance care.
BACKGROUND: Published research suggests Indigenous peoples are less likely to receive analgesia in acute pain settings however there is limited data on the indigenous New Zealand Māori population. The aim of this exploratory pilot study was to compare management between Māori and non-Māori for acute fracture pain in a regional trauma centre.
METHODS: A retrospective review was undertaken for 120 patients with isolated tibial shaft fractures presenting at a tertiary level trauma center between 2015 and 2020. Outcome measures reflected the patient journey including type of analgesia charted pre-hospital, in the ED and on the ward.
RESULTS: Out of 104 matched patients, 48 (46%) were Māori and 65% were male. Fewer Māori received pre-hospital analgesia compared with non-Māori (odds ratio 0.29, p = 0.006). Pain scores were similar on arrival to ED (6.1 ± 3.5 versus 5.4 ± 2.7, p = 0.2). Once at hospital, there were similar rates of prescribed analgesia (paracetamol, NSAIDs, synthetics, or opioids) both in ED and the ward. Time to analgesia were also similar for both groups (72 ± 71 min versus 65 ± 63 min, P > 0.9).
DISCUSSION: We found differences in pre-hospital administration of analgesia between Māori and non-Māori patients with tibial shaft fractures. However once in hospital although there was a trend towards lower prescribing for Māori, there were no significant differences. Exploring the reasons underpinning this difference and the development of robust analgesic guidelines for tibial shaft fractures may help in reducing this inequity in care, particularly in the pre-hospital setting.
Animal studies have shown that this "sublingual" surface can take up antigens and stimulate immune responses, which may have a different character to responses induced by injecting the same antigens. In previous studies of nasal and oral delivery, we used licensed vaccine preparations as pure and well-characterised model antigens safe for use in humans. We will use a licensed "HPV" vaccine as the source of antigens in this study. The quantity and character of responses (lymphocyte number and pattern of surface proteins, concentration and type of antibodies in fluids) will be measured in detail in various anatomical sites (blood, vaginal secretions) before and after delivery of antigens on three occasions. As well as using established immune assays to characterise the responses, we will develop new research assays to detect populations of lymphocytes and antibodies present in secretions. To ensure we have positive samples to include in our assays and validate new techniques, we will recruit some subjects to receive a standard intramuscular injection, as this is known to be nearly 100% reliable in inducing measurable immune responses. As this is a preliminary study we will recruit enough subjects (based on our previous experience with nasal, oral and injected delivery) to ensure we generate sufficient responses we can measure. We may be able to draw some tentative conclusions about differences in character of immune responses following sublingual or injected delivery, but it is not the intention of this initial study to formally compare these two routes. If we observe that sublingual delivery in humans can induce immune responses, we can select assays to test any differences more formally in subsequent bigger and more focused studies.
When recruited from six centers,the participant will be randomized to six groups . In this group participant will receive Celebrex (Celebrex, Capsules, Pfizer Pharmaceuticals Ltd)treatment, which will be applied 1 time daily(one time oral 0.2g) for 4 weeks. The follow-up period is six months.
All enrolled participants have previously received CAB LA as part of the HPTN 083 and HPTN 084 parent studies or their sub-studies. Participants will continue receiving CAB LA 600 mg via gluteal intramuscular (IM) injection.
PURPOSE: Radical surgery is the primary treatment for early-stage resectable lung cancer, yet recurrence after curative surgery is not uncommon. Identifying patients at high risk of recurrence using preoperative computed tomography (CT) images could enable more aggressive surgical approaches, shorter surveillance intervals, and intensified adjuvant treatments. This study aims to analyze lung cancer sites in CT images to predict potential recurrences in high-risk individuals.
METHODS: We retrieved anonymized imaging and clinical data from an institutional database, focusing on patients who underwent curative pulmonary resections for non-small cell lung cancers. Our study used a deep learning model, the Mask Region-based Convolutional Neural Network (MRCNN), to predict cancer locations and assign recurrence classification scores. To find optimized trained weighted values in the model, we developed preprocessing python codes, adjusted dynamic learning rate, and modifying hyper parameter in the model.
RESULTS: The model training completed; we performed classifications using the validation dataset. The results, including the confusion matrix, demonstrated performance metrics: bounding box (0.390), classification (0.034), mask (0.266), Region Proposal Network (RPN) bounding box (0.341), and RPN classification (0.054). The model successfully identified lung cancer recurrence sites, which were then accurately mapped onto chest CT images to highlight areas of primary concern.
CONCLUSION: The trained model allows clinicians to focus on lung regions where cancer recurrence is more likely, acting as a significant aid in the detection and diagnosis of lung cancer. Serving as a clinical decision support system, it offers substantial support in managing lung cancer patients.
In a normal reaction to a wound, such as after surgery, there is stimulation of pain nerves (called c-fibres), swelling and clotting. When people are hospitalized with COVID-19 they usually have a cough (lung c-fibre stimulation), swelling in the lung and clotting.

Bradykinin is a chemical that is released in response to inflammation. It causes C-fibre stimulation, dilation of vessels with oedema (swelling), lowered blood pressure and release of inflammatory cytokines. Normally the production of bradykinin is carefully balanced in the body. Some people have a tendency to release bradykinin. This results in spontaneous swelling - it is called hereditary episodic angioedema (HAE). There has been a treatment for HAE which has been in use since 2008. It is a medication called Icatibant. This blocks the effect of bradykinin at one of its receptors. It is given by injection under the skin. It has a short half life of approximately 1.5 hours.

The primary aim of the study is to see if treatment with Icatibant will improve blood oxygen levels. COVID-19 patients attending hospital with early symptom onset and low oxygen levels will screened for inclusion in the trial. Patients will be randomly allocated into one of two groups. One group will be given the study drug, Icatibant. The other group will be given a placebo injection containing saline water. Patients and research investigators will be blinded to treatment allocation.

Prior to receiving Icatibant/placebo, patients will have baseline measurements carried out. Blood pressure, Mean arterial pressure, heart rate, oxygen saturations and Fraction of inspired oxygen (FiO2) measurement will be carried out. Patients will undergo an arterial blood gas test. Part of the blood taken will be used for the measurement of interleukin-6 (IL-6) and part will be stored for future use. Patients will also have a retinal photograph of both eyes to assess the retinal vessel size. These measurements will be repeated 3 hours after receiving Icatibant/placebo.

A blood sample will also be taken from a group of control participants who do not have COVID-19 infection. The control blood samples will be analysed for IL-6 and part will also be stored for future use. The results will be compared to the baseline blood sample results taken from the COVID-19 positive trial patients.
OBJECTIVE: To describe the clinical trajectories of patients discharged directly from a critical unit to a postacute care facility.
METHODS: This was a retrospective cohort study of patients who were transferred from an intensive care unit or intermediate care unit to a postacute care facility between July 2017 and April 2023. Functional status was measured by the Functional Independence Measure score.
RESULTS: A total of 847 patients were included in the study, and the mean age was 71 years. A total of 692 (82%) patients were admitted for rehabilitation, while 155 (18%) were admitted for palliative care. The mean length of stay in the postacute care facility was 36 days; 389 (45.9%) patients were discharged home, 173 (20.4%) were transferred to an acute hospital, and 285 (33.6%) died during hospitalization, of whom 263 (92%) had a do-not-resuscitate order. Of the patients admitted for rehabilitation purposes, 61 (9.4%) had a worsened functional status, 179 (27.6%) had no change in functional status, and 469 (63%) had an improved functional status during hospitalization. Moreover, 234 (33.8%) patients modified their care goals to palliative care, most of whom were in the group that did not improve functional status. Patients whose functional status improved during hospitalization were younger, had fewer comorbidities, had fewer previous hospitalizations, had lower rates of enteral feeding and tracheostomy, had higher Functional Independence Measure scores at admission to the postacute care facility and were more likely to be discharged home with less complex health care assistance.
CONCLUSION: Postacute care facilities may play a role in the care of patients after discharge from intensive care units, both for those receiving rehabilitation and palliative care, especially for those with more severe illnesses who may not be discharged directly home.
The feasibility of measuring blood glucose concentration in patients with diabetes mellitus using near infrared (NIR) spectroscopy and multivariate data analysis techniques has been established using general purpose, scientific-grade infrared spectrophotometers under the 90-049 UNM HRRC protocol. Now that the concept of painless, bloodless, and reagent-less clinical laboratory tests has been shown to be viable, the challenge is to bring this technology to the patients who need it. We must develop a device that is portable, affordable, and rugged - all while improving accuracy. We must also improve our understanding of the nature of glucose in whole, intact skin. Since the light beam cannot discriminate plasma glucose in skin blood vessels from glucose in the larger skin interstitial fluid space, the exact nature of the glucose in all tissue compartments contributing to the light-beam signal must be elucidated. The noninvasive measurement can be no more accurate than the reference measurement on which it was based. Finally, we have found that the accuracy of the noninvasive measurement also worsens as a function of time from the initial measurement. This effect is independent of instrumentation drift and is due to physical changes in the patient's skin such as variation of hydration, collagen, vascularity, glycation end-products, etc. To account for these sources of physiologic interference they must be evaluated independently and then compared to errors of the noninvasive predictions over time.
Angiotensin II (AngII) has been strongly implicated in hypertension and its complications. Evidence suggests the mechanisms by which angiotensin II (AngII) elevates blood pressure and enhances cardiovascular remodeling and damage may be distinct. In vascular smooth muscle cells, a metaloproteinase ADAM17 mediates epidermal growth factor receptor (EGER) transactivation, which may be responsible for cardiovascular remodeling but not hypertension induced by AngII. Treatment with a human cross-reactive ADAM17 inhibitory antibody (A9B8) also prevented cardiovascular, remodeling and ER stress but not hypertension in C57Bl/6 mice infused with AngII. In vitro data further supported these findings. In conclusion, vascular ADAM17 mediates AngII-induced cardiovascular remodeling via EGFR activation independent of blood pressure regulation. ADAM17 presents a unique therapeutic target for antibodies such as A9B8 for the prevention of hypertensive complications.